SCHEMBL23927045

SCHEMBL23927045

Cc1cc(C#N)cc(C)c1Oc1ccc(Nc2ncccc2[N+](=O)[O-])cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 2/20 0.46
MAPK1 P28482 2/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PIK3CA P42336 2/20 0.37
MTOR P42345 2/20 0.37
PKM P14618 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
PIK3CD O00329 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23927064 0.83 CYP2C9 (0.42) NPC1RAB9AALDH1A1SMN1; SMN2PIK3CA
SCHEMBL30079611 0.83 CYP2C9 (0.42) NPC1RAB9AALDH1A1SMN1; SMN2PIK3CA
SCHEMBL719827 0.79 CYP2C9 (0.47) MAPTMAPK1MEN1KMT2AL3MBTL1
SCHEMBL6347219 0.78 MEN1 (0.62) MAPTNPC1RAB9AMAPK1NFKB1
SCHEMBL31454189 0.76 MAPT (0.64) MAPTNPC1RAB9AMAPK1NFKB1
SCHEMBL9727168 0.76 MAPT (0.64) MAPTNPC1RAB9AMAPK1NFKB1
SCHEMBL15954978 0.76 MAPT (0.56) MAPTNPC1RAB9AMAPK1NFKB1
SCHEMBL23927093 0.76 L3MBTL1 (0.51) MAPTMAPK1MEN1KMT2AL3MBTL1
SCHEMBL31157915 0.74 MAPT (0.43) MAPTNPC1RAB9AMAPK1NFKB1
SCHEMBL717103 0.74 MERTK (0.42) MAPTMAPK1MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
EP-4139306-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2023-03-01 EP disclosed
CN-115380032-A KV3 enhancers for the treatment of cognitive disorders 豪夫迈·罗氏有限公司 2022-11-22 CN disclosed
WO-2021214090-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2021-10-28 WO disclosed
EP-3901152-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2021-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS KCNN3, KCNA4, KCNA3 MAPT 1023/4885NPC1 1693/4885RAB9A 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.